(2R)-2-[[(3aR,4R,5S,7aS)-4-(2-methylphenyl)-2,3,3a,4,5,6,7,7a-octahydro-1H-isoindol-5-yl]oxy]-2-[3,5-bis(trifluoromethyl)phenyl]ethanol | 1070764-34-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R)-2-[[(3aR,4R,5S,7aS)-4-(2-methylphenyl)-2,3,3a,4,5,6,7,7a-octahydro-1H-isoindol-5-yl]oxy]-2-[3,5-bis(trifluoromethyl)phenyl]ethanol
• CAS: 1070764-34-9
• 化学式: C₂₅H₂₇F₆NO₂
• 分子量: 487.485
• InChiKey: ZTVCAAWDJCXRMG-LNMYJNIUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] USE OF NEUROKININ-1 ANTAGONISTS AS ANTITUSSIVES<br/>[FR] UTILISATION D'ANTAGONISTES DE NEUROKININE-1 COMME ANTITUSSIFS
  申请人：MENLO THERAPEUTICS INC

  公开号：WO2018136554A1

  公开（公告）日：2018-07-26

  The disclosure relates to the use of neurokinin- 1 (NK- 1) antagonists, such as serlopitant, MK-0303 or MK-8478, in alleviating or suppressing cough (including acute, subacute and chronic cough) and urge to cough. The cough can have an unknown cause (idiopathic cough) or can be associated with any type of medical condition, such as a respiratory disorder. The NK- 1 antagonist can be delivered by oral inhalation for more rapid peripheral and central antitussive action. Another antitussive agent in addition to the NK-1 antagonist, such as an NMDA receptor antagonist, can optionally be administered for the treatment of the cough or urge to cough, or the cough-associated medical condition.